智通财经APP获悉，据外媒报道，奥洛兹美医疗 (HALO.US) 首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 (EVO.US) ...

据报道，奥洛兹美医疗（HALO.US）首席执行官海伦·托利（Helen Torley）称，公司计划以现金形式融资20亿欧元（合21亿美元）收购德国Evotec公司（EVO.US）。Torley在接受采访时表示：“我们有信心以全额现金交易的方式为这笔交易提供资金。不会动用股权。她表示：“由于我们承担了一些债务，我们强劲的现金流将能够在交易完成后迅速将我们的杠杆率降至两倍。” ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Buying Evotec would give Halozyme other revenue streams. Helen Torley, Halozyme’s CEO, explained the offer in a statement.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...